Edgewise Therapeutics - A Movement in Muscle
Jan 13, 2025 · At Edgewise, we’re bringing our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases – with determination, integrity and a strong commitment to patients.
Edgewise Therapeutics, Inc. (EWTX) - Yahoo Finance
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down
15 hours ago · Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular ...
Cautious Hold Rating for Edgewise Therapeutics Amid Uncertain ...
2 days ago · Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders.
Edgewise Therapeutics Strengthens Leadership Team to Support …
19 hours ago · Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin ...
Edgewise Therapeutics, Inc. - Investor Relations
Dec 16, 2024 · Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. Guided by our approach to targeting the muscle as an organ, we have combined our foundational expertise in muscle biology and small molecule drug discovery to build our proprietary ...
Edgewise Therapeutics Announces Positive Top-Line Data from …
Sep 19, 2024 · EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM. In the...
About Edgewise Therapeutics
At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. We are committed to helping people and families living with them by pursuing a new era of muscle-focused medicines with patients at the center. That’s why we built Edgewise differently.
Muscular Dystrophy and HCM Clinical Trials
Edgewise Therapeutics (Edgewise) is a clinical-stage company dedicated to developing innovative therapies for serious muscle disorders.
Edgewise Therapeutics Strengthens Leadership Team to Support …
20 hours ago · Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin ...
- Some results have been removed